KR20110110355A - 암 치료용 조성물 및 방법 - Google Patents

암 치료용 조성물 및 방법 Download PDF

Info

Publication number
KR20110110355A
KR20110110355A KR1020117019808A KR20117019808A KR20110110355A KR 20110110355 A KR20110110355 A KR 20110110355A KR 1020117019808 A KR1020117019808 A KR 1020117019808A KR 20117019808 A KR20117019808 A KR 20117019808A KR 20110110355 A KR20110110355 A KR 20110110355A
Authority
KR
South Korea
Prior art keywords
kit
composition
inhibitor
anticancer
anticancer composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020117019808A
Other languages
English (en)
Korean (ko)
Inventor
영희 고
Original Assignee
영희 고
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 영희 고 filed Critical 영희 고
Publication of KR20110110355A publication Critical patent/KR20110110355A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020117019808A 2009-01-29 2010-01-29 암 치료용 조성물 및 방법 Ceased KR20110110355A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14838509P 2009-01-29 2009-01-29
US61/148,385 2009-01-29

Publications (1)

Publication Number Publication Date
KR20110110355A true KR20110110355A (ko) 2011-10-06

Family

ID=42396378

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117019808A Ceased KR20110110355A (ko) 2009-01-29 2010-01-29 암 치료용 조성물 및 방법

Country Status (17)

Country Link
US (1) US8022042B2 (enExample)
EP (1) EP2391363B1 (enExample)
JP (2) JP6068803B2 (enExample)
KR (1) KR20110110355A (enExample)
CN (1) CN102387801A (enExample)
AU (1) AU2010208062B2 (enExample)
CA (2) CA3024263A1 (enExample)
DK (1) DK2391363T3 (enExample)
ES (1) ES2607211T3 (enExample)
HR (1) HRP20161686T1 (enExample)
HU (1) HUE032389T2 (enExample)
IL (1) IL214349A (enExample)
NZ (1) NZ594434A (enExample)
PL (1) PL2391363T3 (enExample)
PT (1) PT2391363T (enExample)
SI (1) SI2391363T1 (enExample)
WO (1) WO2010088564A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324175B2 (en) 2006-02-16 2012-12-04 Young Hee Ko Compositions and methods for the treatment of cancer
US9211377B2 (en) 2009-07-30 2015-12-15 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
CN103610671A (zh) * 2013-12-10 2014-03-05 江苏长泰药业有限公司 丙酮酸药物组成及其在制备治疗肺癌药物中的用途
EP3293167A1 (en) 2016-09-09 2018-03-14 Université Catholique De Louvain [18f]-labelled lactate derivative as pet radiotracer
US10434113B2 (en) 2016-12-16 2019-10-08 The Charlotte Mecklenburg Hospital Authority Compositions and methods for treating muscular dystrophy and other disorders
US10245235B2 (en) 2016-12-16 2019-04-02 The Charlotte-Mecklenburg Hospital Authority Compositions and methods for treating muscular dystrophy and other disorders
KR102623283B1 (ko) * 2017-03-15 2024-01-11 루넬라 바이오테크 인코포레이티드 미토리보신: 암 세포, 박테리아, 및 병원성 효모를 표적으로 하는 미토콘드리아 기반의 치료제
EP4504152A2 (en) * 2022-04-06 2025-02-12 Young Hee Ko Liquid-dispersible halopyruvate formulations and associated methods
CN116375769B (zh) * 2023-03-10 2024-12-03 云南贵金属实验室有限公司 一种双靶点Pt(Ⅳ)抗癌前药及其制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3360633D1 (en) 1982-02-12 1985-10-03 Unitika Ltd Anti-cancer device
US5800820A (en) 1989-01-10 1998-09-01 Repligen Corporation Methods and compositions for treatment of angiogenic diseases
US5759837A (en) 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
US5284786A (en) * 1992-08-14 1994-02-08 National Semiconductor Corporation Method of making a split floating gate EEPROM cell
US5854067A (en) 1996-01-19 1998-12-29 Board Of Regents, The University Of Texas System Hexokinase inhibitors
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6214879B1 (en) 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
US6284786B1 (en) 1999-02-16 2001-09-04 The Center For The Improvement Of Human Functioning, Int'l., Inc. Treatment of cancer using lipoic acid in combination with ascorbic acid
US20020006915A1 (en) 2000-02-15 2002-01-17 Mack Strong Vivian E. Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation
US6448030B1 (en) 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
WO2001068667A1 (en) 2000-03-14 2001-09-20 The Johns Hopkins University School Of Medicine Arrest of proliferation of highly glycolytic tumors
US6670330B1 (en) * 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
AU2002233916A1 (en) 2000-08-03 2002-04-29 Albert Einstein College Of Medicine Isocitrate lyase enzyme from mycobacterium tuberculosis and inhibitory agents to combat persistent infection
US7381713B2 (en) 2000-12-04 2008-06-03 Sioan-Kettering Institute For Cancer Research Treatment of cancer by reduction of intracellular energy and pyrimidines
US7547673B2 (en) * 2001-09-13 2009-06-16 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
EP1526865A4 (en) 2002-08-05 2009-09-02 Mirus Bio Corp COMPOUNDS FOR TARGETING HEPATIC CELLS
CA2498130A1 (en) 2002-09-05 2004-03-18 Invitrogen Corporation Compositions and methods for synthesizing nucleic acids
US20040229826A1 (en) * 2002-12-12 2004-11-18 Larry Norton Dose-dense & sequential adjuvant cancer chemotherapy
US6979675B2 (en) 2003-01-10 2005-12-27 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
EP1610778A4 (en) 2003-01-17 2006-05-31 Threshold Pharmaceuticals Inc TREATMENT OF BENIGNER PROSTATE HYPERPLASIA
US20060172953A1 (en) 2003-01-17 2006-08-03 Threshold Pharmaceuticals Inc. Treatment of benign prostatic hyperplasia using energolytic agents
AU2005274165A1 (en) * 2004-07-28 2006-02-23 Board Of Regents, The University Of Texas System 3-halo-2-oxopropionate salts and esters as novel anticancer agents
JP2008540566A (ja) * 2005-05-12 2008-11-20 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド ２−デオキシグルコースを用いたがんの処置
US7754693B2 (en) * 2006-02-16 2010-07-13 Young Hee Ko Composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
EP2114413B1 (en) 2006-12-18 2014-10-22 The Johns Hopkins University Therapeutics for treating cancer using 3-bromopyruvate

Also Published As

Publication number Publication date
CA2750944A1 (en) 2010-08-05
EP2391363B1 (en) 2016-09-28
CA3024263A1 (en) 2010-08-05
US20100197612A1 (en) 2010-08-05
HRP20161686T1 (hr) 2017-02-24
ES2607211T3 (es) 2017-03-29
JP2015180680A (ja) 2015-10-15
JP6068803B2 (ja) 2017-01-25
WO2010088564A2 (en) 2010-08-05
EP2391363A2 (en) 2011-12-07
AU2010208062A1 (en) 2011-08-18
PL2391363T3 (pl) 2017-03-31
CN102387801A (zh) 2012-03-21
US8022042B2 (en) 2011-09-20
SI2391363T1 (sl) 2017-01-31
IL214349A0 (en) 2011-09-27
HUE032389T2 (en) 2017-09-28
DK2391363T3 (en) 2017-01-16
IL214349A (en) 2015-02-26
EP2391363A4 (en) 2012-09-19
AU2010208062B2 (en) 2014-07-24
WO2010088564A3 (en) 2010-12-29
CA2750944C (en) 2019-01-08
JP2012516358A (ja) 2012-07-19
NZ594434A (en) 2014-11-28
PT2391363T (pt) 2016-12-23

Similar Documents

Publication Publication Date Title
US11077078B2 (en) Compositions and methods for the treatment of cancer
KR20110110355A (ko) 암 치료용 조성물 및 방법
EP2063881B1 (en) A composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
US20240382512A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
AU2013202507B2 (en) Inhibition of drug resistant cancer cells
HK1168543A (en) Compositions and methods for the treatment of cancer
CN102083428A (zh) 采用长时间连续输液Belinostat进行治疗的方法
EP4626440A1 (en) Heavy isotope 3-bp molecules, compositions, and treatments
JPWO2006035673A1 (ja) 虚血性心臓傷害の新保護法
AU2015218471A1 (en) Inhibition of drug resistant cancer cells

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110826

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150129

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160118

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20161109

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160118

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I